Therapeutic Development Services
Hairy cell leukemia (HCL) is an uncommon form of B-cell cancer. In order to solve the difficulties associated with managing HCL, Protheragen has invested in advanced technologies and professionals aimed at developing innovative treatment options. Our tailored solutions will help facilitate the entire process from development of a therapeutic candidate to commercialization.
Hairy cell leukemia or HCL is a slow-growing rare blood cancer which is characterized by the abnormal proliferation of B lymphocytes. Though typically classified as indolent, HCL can lead to life-threatening complications like bone marrow failure, cytopenic states, and increased infection risk due to opportunistic immunosuppression.
Fig.1 Cytological aspects of hairy cell leukemia (HCL). (Paillassa, Jérôme, and Xavier Troussard., 2020)
Hairy cell leukemia (HCL) results from the oncogenic change of B cells. This process is driven primarily by the mutation of BRAF V600E, leading to activation of MAPK/ERK, thus enabling excess proliferation and survival of B cells. These B cells usually have a distinctive “hairy” appearance because of cytoplasmic projections and characteristically express CD20, CD11c, CD25, and CD103.
Fig.2 Pathogenesis of classic hairy cell leukemia (HCL). (Bohn, Jan-Paul, et al., 2021)
| Drug Names | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| Moxetumomab Pasudotox | Delivers bacterial toxin to CD22+ cells and induces apoptosis. | CD22 | NCT01829711 | Approved |
| Vemurafenib and Rituximab | Vemurafenib: Blocks MAPK pathway. Rituximab: Induces ADCC/CDC. |
BRAF V600E/CD20 | NCT05388123 | Phase II |
| Cladribine and Rituximab | Cladribine: Inhibits DNA synthesis. Rituximab: Induces ADCC/CDC. |
DNA/CD20 | NCT00412594 | Phase II |
| Ibrutinib | Blocks BCR signaling and reduces survival of malignant B-cells. | BTK | NCT01841723 | Phase II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Protheragen strives to provide best-in-class diagnostic and therapeutic development solutions specifically for hairy cell leukemia (HCL). We are also involved in the development of sophisticated disease models that facilitate preclinical research towards possible therapies. We provide our clients with innovative and advanced solutions that pave the way for effective intervention strategies.
Therapeutic Development Services
As a premier provider of therapeutic development solutions, Protheragen is dedicated to pioneering a diverse range of groundbreaking therapies for hairy cell leukemia (HCL) aimed at tackling the intricate obstacles within this domain.
Our expertise lies in the development of precise animal models that mimic the characteristics of hairy cell leukemia (HCL). These models provide a controlled setting for the preclinical evaluation of prospective therapies.
Protheragen provides integrated services of pharmacodynamics (PD), pharmacokinetic (PK), and toxicology research in relation to the therapy development for hairy cell leukemia (HCL). If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)
